<DOC>
	<DOCNO>NCT02007343</DOCNO>
	<brief_summary>This study aim assess large additional disease burden extra cost generate antibiotic resistance patient suffer infection cause gram-negative bacteria , Escherichia coli Pseudomonas aeruginosa , hospital Netherlands .</brief_summary>
	<brief_title>Burden Antibiotic Resistance Gram-Negative Infections Dutch Hospitals</brief_title>
	<detailed_description>This study address follow three aim : 1 . To provide accurate estimate currently available incremental disease burden attributable cost antibiotic-resistant compare antibiotic-sensitive gram-negative bacteria ( i.e . Enterobacteriaceae non-fermenters ) . This analysis focus gram-negative infection patient hospitalize . In less detailed manner , analysis disease burden cost perform acquire gram-negative infection hospitalization . 2 . To identify determinant associate resistance gram-negative infection , extent confounders relation resistance outcome . 3 . To adapt optimize exist methodology measure burden resistance , among others calculate disability-adjusted life year ( DALYs ) incorporate merely mortality , also morbidity . GRAND-ABC design prospective parallel match cohort , run year eight participating hospital . The primary cohort random sample Gram-negative infection occur participate hospital study period . This cohort divide basis primary determinant status ( whether Gram-negative pathogen resistant base Dutch guideline multi-drug resistant organism ; Werkgroep Infectiepreventie ( WIP ) . Bijzonder resistente micro-organismen ( BRMO ) . December 2012. http : //www.wip.nl/free_content/Richtlijnen/130424_BRMO.pdf ) two parallel subcohorts . Each patient subcohorts match one patient without gram-negative infection . Together form secondary cohort non-infected patient : patient admit hospital study period within risk set infected patient . For patient data collection perform review medical file , cover entire admission include study , cause 30 day mortality . Data collection hospital stay cover confounders effect modifier association study , feed outcomes cost , DALYs length stay . For cohort gram-negative infection , data infection parameter antibiotic treatment parameter also collect . In addition , subcohort infection multi-drug resistant organism random 20 % subcohort infection sensitive organism select follow-up , consist send questionnaire renew medical file review 30 day index culture date . In case ongoing sequelae gram-negative infection , procedure repeat 90 day index culture date . These questionnaire fee outcome cost , DALYs quality-adjusted life year ( QALYs ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Negative Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Please refer description two cohort Patients child 's ward Patients admit ward longterm care psychiatric ward , subsequently admit acute care ward consequence infection Patients admit ward exclude logistic reason nonavailability electronic patient file , subsequently admit include acute care ward consequence infection Patients include cohort infect patient hospitalization within past 30 ( eligible followup ) 90 ( eligible followup ) day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Enterobacteriaceae</keyword>
	<keyword>Pseudomonas</keyword>
	<keyword>Acinetobacter</keyword>
	<keyword>Stenotrophomonas</keyword>
	<keyword>Mortality</keyword>
	<keyword>Morbidity</keyword>
	<keyword>Cost Illness</keyword>
	<keyword>Causality</keyword>
	<keyword>Multicenter Study</keyword>
	<keyword>Cohort Studies</keyword>
	<keyword>Case-Control Studies</keyword>
	<keyword>Prospective Studies</keyword>
	<keyword>Follow-up Studies</keyword>
</DOC>